Dr Jiwon Oh (University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy.
The abstract entitled: ‘The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the rationale for the use of BTK inhibitors in MS? (0:14)
- How does fenebrutinib differ from other agents in its class in terms of suitability as an MS therapy? (1:20)
- What autoimmune indications were included in your safety analysis? (3:41)
- What were the findings of this analysis? (4:30)
- What were the conclusions in terms of potential use at high doses in MS patients? (6:51)
Jiwon Oh has received personal compensation for consulting or speaking from EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, BMS, and Roche, and has received research funding from the MS Society of Canada, the National MS Society, Brain Canada, Biogen-Idec, Roche, and EMD-Serono.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2021: Flushing and Flushing-related Adverse Events – Results from the Phase 3 EVOLVE-MS-2 Study
It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis. The abstract […]
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!